NPI: 1174601397 · PALMETTO BAY, FL 33157 · General Acute Care Hospital · NPI assigned 11/02/2006
Authorized official KNIGHT, MARK controls 20+ related entities in our dataset. Read more
| Authorized Official | KNIGHT, MARK (CHIEF FINANCIAL OFFICER) |
| Parent Organization | PUBLIC HEALTH TRUST OF MIAMI DADE COUNTY |
| NPI Enumeration Date | 11/02/2006 |
Other providers sharing the same authorized official: KNIGHT, MARK
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 35,377 | $832K |
| 2019 | 98,870 | $1.88M |
| 2020 | 82,675 | $1.02M |
| 2021 | 87,527 | $1.26M |
| 2022 | 87,069 | $1.80M |
| 2023 | 35,957 | $918K |
| 2024 | 13,431 | $307K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 99284 | Emergency department visit for the evaluation and management, high severity | 17,422 | 14,802 | $1.11M |
| 99283 | Emergency department visit for the evaluation and management, moderate severity | 12,880 | 11,394 | $924K |
| 99285 | Emergency department visit for the evaluation and management, high severity with immediate threat to life | 12,662 | 10,107 | $773K |
| 80053 | Comprehensive metabolic panel | 28,646 | 19,184 | $475K |
| G0378 | Hospital observation service, per hour | 12,444 | 6,393 | $474K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2,065 | 1,810 | $321K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 2,915 | 2,536 | $263K |
| 70450 | Computed tomography, head or brain; without contrast material | 4,922 | 3,984 | $261K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2,080 | 1,713 | $248K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1,780 | 1,522 | $200K |
| 80048 | Basic metabolic panel (calcium, ionized) | 9,832 | 7,059 | $183K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 4,374 | 1,145 | $173K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2,092 | 1,828 | $162K |
| 96361 | Intravenous infusion, hydration; each additional hour | 2,921 | 2,404 | $162K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 6,096 | 4,967 | $159K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 4,121 | 3,483 | $109K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 39,130 | 24,341 | $101K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 325 | 307 | $85K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 4,796 | 2,300 | $75K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 3,979 | 1,918 | $70K |
| 76819 | Fetal biophysical profile; without non-stress testing | 1,493 | 1,035 | $66K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 4,087 | 3,268 | $64K |
| 99215 | Prolong outpt/office vis | 703 | 650 | $59K |
| 86850 | 2,750 | 2,287 | $57K | |
| 84703 | 8,044 | 7,007 | $52K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 1,429 | 1,036 | $51K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1,436 | 1,280 | $50K |
| 97162 | 2,338 | 1,774 | $48K | |
| 99213 | Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 632 | 505 | $45K |
| 81001 | 13,195 | 11,133 | $41K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 638 | 543 | $39K |
| 71045 | Radiologic examination, chest; single view | 11,886 | 9,205 | $37K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 426 | 371 | $37K |
| 84484 | 14,383 | 7,294 | $34K | |
| 86803 | 9,206 | 7,967 | $34K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 721 | 286 | $33K |
| 96375 | Therapeutic injection; each additional sequential IV push | 2,660 | 2,209 | $33K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 1,790 | 898 | $32K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 2,430 | 2,126 | $30K |
| 85610 | 10,965 | 8,445 | $30K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | 1,548 | 1,319 | $29K |
| 85730 | 9,821 | 7,732 | $29K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 11,322 | 8,878 | $28K |
| 72125 | Computed tomography, cervical spine; without contrast material | 993 | 818 | $26K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | 746 | 689 | $25K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | 1,151 | 1,002 | $23K |
| 93017 | 363 | 295 | $22K | |
| 87631 | 789 | 699 | $22K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 3,348 | 2,932 | $22K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 166 | 127 | $21K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 4,281 | 3,261 | $20K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 5,786 | 4,273 | $17K |
| 84702 | 2,964 | 2,029 | $17K | |
| 71046 | Radiologic examination, chest; 2 views | 1,770 | 1,542 | $17K |
| 83690 | 4,708 | 3,875 | $17K | |
| 83050 | 1,826 | 1,110 | $16K | |
| 76801 | 1,279 | 1,071 | $14K | |
| 86900 | 2,869 | 2,399 | $14K | |
| 87186 | 1,506 | 1,105 | $14K | |
| 99214 | Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 168 | 152 | $13K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 5,632 | 4,448 | $13K |
| 86901 | 2,920 | 2,449 | $13K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 3,658 | 3,063 | $12K |
| 93971 | 317 | 268 | $12K | |
| 73630 | 680 | 559 | $12K | |
| J1644 | Injection, heparin sodium, per 1000 units | 2,481 | 840 | $11K |
| 72131 | 203 | 184 | $11K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 1,320 | 538 | $10K |
| 82803 | 1,938 | 1,183 | $10K | |
| 84443 | Thyroid stimulating hormone (TSH) | 3,219 | 2,478 | $10K |
| 82550 | 5,573 | 3,518 | $10K | |
| J1815 | Injection, insulin, per 5 units | 3,571 | 1,177 | $9K |
| 80061 | Lipid panel | 2,348 | 1,803 | $9K |
| J1170 | Injection, hydromorphone, up to 4 mg | 2,517 | 1,415 | $8K |
| 93970 | 380 | 319 | $8K | |
| 83880 | 2,672 | 1,864 | $8K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 105 | 93 | $8K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 3,174 | 2,129 | $8K |
| 92586 | 144 | 141 | $8K | |
| 82375 | 1,834 | 1,110 | $7K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | 3,452 | 1,423 | $7K |
| 81003 | 1,222 | 1,013 | $7K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | 469 | 391 | $7K |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 153 | 135 | $7K |
| J2270 | Injection, morphine sulfate, up to 10 mg | 2,625 | 1,592 | $6K |
| 87077 | 1,731 | 1,194 | $6K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 304 | 269 | $6K |
| 82330 | 1,718 | 1,063 | $6K | |
| 99205 | Prolong outpt/office vis | 93 | 84 | $6K |
| 73562 | 633 | 534 | $6K | |
| 86703 | 5,971 | 5,171 | $6K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 2,137 | 1,697 | $6K |
| 72100 | 674 | 602 | $5K | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 163 | 144 | $5K |
| 87040 | 1,949 | 892 | $5K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 2,252 | 1,842 | $5K |
| 80320 | 2,540 | 2,169 | $5K | |
| 83735 | 3,293 | 2,267 | $5K | |
| 70498 | 15 | 13 | $5K | |
| J0690 | Injection, cefazolin sodium, 500 mg | 1,648 | 994 | $4K |
| 73030 | 357 | 299 | $4K | |
| 82553 | 1,987 | 830 | $4K | |
| 87070 | 546 | 444 | $4K | |
| 82947 | 1,577 | 960 | $4K | |
| 97014 | 92 | 44 | $3K | |
| 97010 | 246 | 90 | $3K | |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | 324 | 211 | $3K |
| 80051 | 1,547 | 953 | $3K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 149 | 48 | $3K |
| 76830 | Ultrasound, transvaginal | 314 | 289 | $3K |
| 83036 | Hemoglobin; glycosylated (A1C) | 1,542 | 1,218 | $3K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 1,670 | 1,235 | $3K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 768 | 616 | $3K |
| 82150 | 471 | 414 | $3K | |
| 73610 | 249 | 217 | $2K | |
| 83605 | 1,494 | 929 | $2K | |
| 80329 | 2,233 | 1,279 | $2K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 1,755 | 1,459 | $2K |
| 73130 | 213 | 183 | $2K | |
| 74174 | 15 | 14 | $2K | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 493 | 289 | $2K |
| 87430 | 208 | 197 | $2K | |
| 87340 | 405 | 185 | $2K | |
| 86140 | 1,392 | 1,045 | $2K | |
| 85379 | 1,364 | 1,016 | $2K | |
| C9113 | Injection, pantoprazole sodium, per vial | 502 | 301 | $2K |
| J2060 | Injection, lorazepam, 2 mg | 1,189 | 917 | $2K |
| 70486 | 56 | 52 | $2K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 577 | 497 | $2K |
| 81025 | 160 | 152 | $1K | |
| 92587 | 32 | 29 | $1K | |
| J3490 | Unclassified drugs | 1,287 | 718 | $1K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 423 | 396 | $1K |
| J1940 | Injection, furosemide, up to 20 mg | 175 | 81 | $1K |
| 97166 | 297 | 223 | $1K | |
| 99204 | Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 14 | 14 | $1K |
| 90715 | 724 | 610 | $1K | |
| J1956 | Injection, levofloxacin, 250 mg | 270 | 159 | $1K |
| 87205 | 118 | 86 | $1K | |
| J2785 | Injection, regadenoson, 0.1 mg | 98 | 81 | $1K |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 602 | 515 | $1K |
| 74240 | 48 | 36 | $1K | |
| 88304 | 438 | 323 | $1K | |
| 92558 | 122 | 117 | $1K | |
| 85652 | 600 | 493 | $1K | |
| 74018 | 144 | 120 | $843.16 | |
| 99203 | Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 14 | 12 | $803.37 |
| 82728 | 649 | 414 | $727.08 | |
| 84132 | 1,249 | 776 | $672.18 | |
| 97535 | Self-care/home management training, each 15 minutes | 92 | 55 | $667.32 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 338 | 119 | $564.77 |
| 82435 | 1,074 | 657 | $560.53 | |
| 94760 | 52 | 37 | $544.09 | |
| 72040 | 30 | 30 | $530.00 | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 64 | 37 | $529.10 |
| 97116 | 381 | 196 | $457.04 | |
| 80076 | 78 | 70 | $454.97 | |
| 85007 | 133 | 105 | $423.39 | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 315 | 251 | $395.22 |
| 80164 | 19 | 15 | $348.26 | |
| 76770 | 31 | 24 | $304.13 | |
| J1630 | Injection, haloperidol, up to 5 mg | 360 | 283 | $277.88 |
| C1776 | Joint device (implantable) | 27 | 24 | $268.97 |
| 86702 | 14 | 12 | $267.40 | |
| 80069 | 30 | 12 | $262.01 | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | 38 | 12 | $249.92 |
| 92650 | 113 | 93 | $249.86 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 154 | 52 | $234.43 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 12 | 12 | $214.15 |
| 73502 | 18 | 13 | $184.35 | |
| 71250 | 32 | 24 | $175.91 | |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 16 | 12 | $171.77 |
| 83540 | 136 | 95 | $156.22 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 72 | 51 | $146.65 |
| 83615 | 566 | 353 | $139.01 | |
| 87075 | 26 | 12 | $126.45 | |
| 93880 | 33 | 25 | $122.89 | |
| 00731 | 42 | 40 | $110.32 | |
| 82009 | 43 | 26 | $102.32 | |
| 73110 | 29 | 28 | $99.65 | |
| J0692 | Injection, cefepime hydrochloride, 500 mg | 100 | 52 | $96.53 |
| J3370 | Injection, vancomycin hcl, 500 mg | 249 | 145 | $94.32 |
| 84439 | 52 | 37 | $87.23 | |
| A9270 | Non-covered item or service | 250 | 131 | $80.52 |
| 85027 | 275 | 212 | $76.01 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 636 | 515 | $73.32 |
| 84100 | 332 | 232 | $71.95 | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | 12 | 12 | $55.16 |
| J1953 | Injection, levetiracetam, 10 mg | 16 | 12 | $47.64 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 105 | 14 | $41.37 |
| 85384 | 67 | 37 | $38.23 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 12 | 12 | $37.78 |
| 82607 | 96 | 71 | $35.31 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | 31 | 12 | $31.44 |
| 83550 | 64 | 41 | $30.92 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 44 | 40 | $29.46 |
| 84145 | 97 | 79 | $21.29 | |
| 86701 | 14 | 12 | $17.06 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 114 | 96 | $13.79 |
| 82746 | 59 | 44 | $7.79 | |
| 82570 | 14 | 12 | $3.15 | |
| C9399 | Unclassified drugs or biologicals | 471 | 382 | $0.00 |
| 73560 | 37 | 27 | $0.00 | |
| J2704 | Injection, propofol, 10 mg | 171 | 159 | $0.00 |
| G9019 | Oseltamivir phosphate, oral, per 75 mg (for use in a medicare-approved demonstration project) | 37 | 29 | $0.00 |
| 88311 | 13 | 12 | $0.00 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 69 | 56 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 29 | 26 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 31 | 24 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 16 | 12 | $0.00 |